Skip to main content

Table 3 Genotype and allele counts for NOD1/CARD4 variants in New Zealand IBD patients and in New Zealand Caucasians

From: Nucleotide-binding oligomerization domain containing 1 (NOD1) haplotypes and single nucleotide polymorphisms modify susceptibility to inflammatory bowel diseases in a New Zealand caucasian population: a case-control study

SNP Controls CD UC CD+UC
  n (%) n (%) OR
(95% CI)
n (%) OR
(95% CI)
n (%) OR
(95% CI)
NOD1 rs2075818        
CC 105 (52.2) 255 (66.7) 1.29
(0.56–2.98)
226 (56.5) 0.61
(0.28–1.31)
481 (61.4) 0.84
(0.40–1.77)
CG 87 (43.3) 111 (29.0) 0.68
(0.29–1.59)
142 (35.5) 0.46
(0.21–1.01)
253 (32.3) 0.53
(0.25–1.13)
GG 9
(4.5)
17 (4.4) 1.00 32 (8.0) 1.00 49 (6.3) 1.00
Genotype p-value   0.002 0.08 0.01
HWE p-value 0.10 0.28 0.15 0.05
G 105 (26.1) 145 (18.9) 206 (25.8) 351 (22.4)
C 297 (73.9) 621 (81.1) 594 (74.3) 1215 (77.6)
OR (95% CI)   0.66 (0.49–0.89) 0.98 (0.74–1.30) 0.82 (0.63–1.06)
Allelic p-value   0.004 0.89 0.12
NOD1 rs2075822        
CC 20 (10.0) 28
(7.3)
1.00 17
(4.2)
1.00 45
(5.7)
1.00
CT 60 (30.0) 122 (31.9) 1.45
(0.76–2.79)
135 (33.6) 2.65
(1.29–5.41)
257 (32.8) 1.90
(1.05–3.46)
TT 120 (60.0) 232 (60.7) 1.38
(0.75–2.55)
250 (62.2) 2.45
(1.23–4.85)
482 (61.5) 1.79
(1.02–3.14)
Genotype p-value   0.52 0.02 0.09
HWE p-value 0.007 0.04 0.82 0.17
C 100 (25.0) 178 (23.3) 169 (21.0) 347 (22.1)
T 300 (75.0) 586 (76.7) 635 (79.0) 1221 (77.9)
OR (95% CI)   0.91 (0.69–1.21) 0.80 (0.60–1.06) 0.85 (0.66–1.10)
Allelic p-value   0.52 0.12 0.22
NOD1 rs2907748        
AA 21 (10.3) 31
(8.2)
1.00 20
(5.0)
1.00 51
(6.6)
1.00
AG 73 (36.7) 129 (34.3) 1.20
(0.64–2.23)
161 (40.3) 2.32
(1.18–4.53)
290 (37.4) 1.64
(0.93–2.89)
GG 105 (52.8) 216 (57.4) 1.39
(0.76–2.54)
219 (54.7) 2.19
(1.14–4.22)
435 (56.1) 1.71
(0.98–2.96)
Genotype p-value   0.48 0.04 0.16
HWE p-value 0.12 0.07 0.16 0.78
A 115 (28.9) 191 (25.4) 201 (25.1) 392 (25.3)
G 283 (71.1) 561 (74.6) 599 (74.9) 1160 (74.7)
OR (95% CI)   0.84 (0.64–1.10) 0.83 (0.63–1.08) 0.83 (0.65–1.06)
Allelic p-value   0.20 0.16 0.14